#USA #Irvine #liver cancer #Health Policy #Helio Genomics

Urgent Call for Liver Cancer Surveillance

As the number of liver cancer fatalities in the United States approaches 31,000 annually, a duo of congressmen is making impactful strides by pressing Health and Human Services Secretary Robert F. Kennedy Jr. to prioritize liver cancer surveillance on a national level. This initiative comes as part of an urgent response to the alarming statistics surrounding liver disease diagnoses, particularly among patients suffering from cirrhosis or chronic hepatitis B.

Legislative Push for Surveillance Standards

Representatives Don Bacon (R-NE) and Mike Carey (R-OH) recently sent a letter urging Secretary Kennedy to implement a national surveillance strategy for liver cancer. Their message highlights a concerning trend where high-risk individuals are often diagnosed too late—after curative options like surgery or transplants are no longer viable. The American Cancer Society forecasts 42,340 new cases of liver and intrahepatic bile duct cancer and approximately 30,980 deaths in 2026 alone, underlining the critical need for effective surveillance.

Dr. Bharat Tewarie, CEO of Helio Genomics, supports this initiative, stating, "Patients die of a cancer we already know how to find." He emphasizes that all high-risk individuals should undergo routine surveillance, advocating for a standardized approach that includes a specialized blood test tailored for liver cancer detection amongst those with cirrhosis.

The Reality of Current Screening Practices

Despite existing recommendations suggesting biannual checks for individuals with cirrhosis or chronic hepatitis B, compliance is worryingly low. Studies indicate that as few as 9% of those with cirrhosis engage in regular surveillance, with overall compliance rates estimated to be below 25%. Traditional screening methods, particularly ultrasounds, often overlook smaller tumors, making the case for innovative testing solutions.

In response to this glaring gap in effective monitoring, Helio Genomics is advocating for a national standard that would place every eligible high-risk patient into an active surveillance program. Their approach leverages the HelioLiver™ blood test, which demonstrates superior performance in detecting liver tumors compared to conventional ultrasound techniques.

The Call for Change

The congressmen's letter to Secretary Kennedy underscores the need for a comprehensive directive prioritizing liver cancer surveillance within the U.S. Preventive Services Task Force (USPSTF). An official recommendation from the task force could significantly enhance surveillance practices for the millions at risk, directly addressing the urgent need for life-saving interventions among this vulnerable population.

Helio Genomics, based in Irvine, California, is at the forefront of this vital conversation. With its advanced testing capabilities, Helio aims to facilitate earlier cancer detection, thus improving patient outcomes and potentially saving lives.

A Look at HelioLiver™

HelioLiver™, Helio Genomics' leading product, is a blood-based test designed for the early detection of hepatocellular carcinoma (HCC), the predominant form of liver cancer. By harnessing patterns of cell-free DNA methylation alongside other biomarkers and demographic data, the test is tailored to identify cancer in high-risk patients more effectively than traditional imaging methods.

The disparities in health outcomes due to inadequate surveillance can be pivotal in changing the narrative for those with liver disease. With proactive measures and advocacy like that of Bacon and Carey, there is hope for implementing a national surveillance standard capable of addressing the growing challenges posed by liver cancer.

In conclusion, as lawmakers intensify their push for standardized liver cancer surveillance, the collaboration of clinical innovators like Helio Genomics could pave the way for a brighter future in healthcare, reducing the alarming death toll and improving the lives of countless patients battling this silent but deadly disease.